Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 165 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetes
Interventions
Glimepiride, Liraglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
3,474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Obesity & Overweight, Diabetes (DM)
Interventions
Glucagon-Like Peptide-1 Agonist (GLP-1)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Type 1 Diabetes
Interventions
Victoza, Placebo, Dapagliflozin 10mg Tab
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, sitagliptin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
58
States / cities
Phoenix, Arizona • Tucson, Arizona • Escondido, California + 46 more
Terminated Phase 3 Interventional Results available

Binge Eating Liraglutide Intervention

NCT03279731
Conditions
Binge-Eating Disorder
Interventions
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml, Placebo
Drug
Lead sponsor
Kelly Allison
Other
Eligibility
21 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Obesity
Interventions
Saxenda®, Placebo
Drug · Other
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Lubbock, Texas
Active, not recruiting No phase listed Observational

Anti-obesity Pharmacotherapy and Inflammation

NCT05756764
Conditions
Obesity
Interventions
Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
35 Years to 60 Years
Enrollment
30 participants
Timeline
2023 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana
Conditions
Type 2 Diabetes Mellitus
Interventions
OPTIFAST
Other
Lead sponsor
Moahad S Dar
Other
Eligibility
25 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Greenville, North Carolina
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
7 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Anaheim, California • New Haven, Connecticut • Jacksonville, Florida + 6 more
Conditions
Obesity
Interventions
Weight Management Program (WMP), Medication for chronic weight management (Rx)
Other · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

NCT06533527
Conditions
Diabetes Mellitus, Type 2, Obesity, Gastroparesis
Interventions
GLP-1 medication
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Weston, Florida • Cleveland, Ohio
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
44
States / cities
Anaheim, California • Garden Grove, California • La Jolla, California + 39 more
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
70
States / cities
Little Rock, Arkansas • Concord, California • Encino, California + 60 more
Conditions
Diabetes Mellitus, Type 2
Interventions
DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
Conditions
Diabetes Mellitus, Type 2, Diabetes
Interventions
Metformin, Detemir, Liraglutide, Insulin Aspart
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Type2 Diabetes
Interventions
Exercise, Liraglutide
Other · Drug
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Recruiting Phase 4 Interventional Accepts healthy volunteers

Fibrosis Lessens After Metabolic Surgery

NCT06374875
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Interventions
Metabolic surgery, Incretin-Based Therapy
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
4
States / cities
Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more
Conditions
Obesity
Interventions
GSK2890457, Metformin, Placebo, Liraglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Overland Park, Kansas
Active, not recruiting Phase 4 Interventional

Liraglutide Effect in Atrial Fibrillation

NCT03856632
Conditions
Atrial Fibrillation
Interventions
Liraglutide, RFM, Anti Arrhythmics, Afib Catheter Ablation
Drug · Other · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Miami, Florida
Conditions
Type 1 Diabetes
Interventions
Closed loop with sensor and Insulin, Closed loop with sensor, Insulin and Liraglutide
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
56
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 47 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
65 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more
Conditions
Type 1 Diabetes
Interventions
ePID closed loop system, liraglutide
Device · Drug
Lead sponsor
Jennifer Sherr
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Santa Monica, California • Baltimore, Maryland • Buffalo, New York + 2 more